Market Access has moved from a supporting consideration to a major influence on Commercial Performance in Pharma. In this episode, Abhay Jajoo, Rickey Mehta, and Geoff Woodall trace that evolution—from a 1990s model dominated by Salesforce activity, to the rise of Marketing Mix and Digital Engagement, and ultimately to an environment where Payer Control, Formulary Restrictions, Pricing, Reimbursement, and Access Strategy can materially shape Brand Performance.
Episode Highlights
- 04:10 The evolution of Pharma Commercial Influence from Sales Force-led promotion to a model where Market Access plays a much larger role.
- 06:00 Why incremental sales have become smaller over time as Pharma portfolios have shifted toward chronic products with higher carryover.
- 07:00 How Market Access has grown to influence a significant share of incremental sales, and what that means for commercial strategy.
- 08:00 A real-world brand example showing how carryover, promotion, and Market Access contribute differently to Sales across customer segments.
- 22:08 How payer dynamics can overturn conventional targeting assumptions, including an example where 52% of the market opportunity sat with non-called-on physicians.
- 37:16 The analytics journey from Data Enablement and Hygiene to BI, Advanced Analytics, and Data Science, and the impact of reducing data wrangling.
- 44:57 How a platform-led approach can accelerate the journey from analytics foundations to actionable insights and faster deployment.
Key Takeaways
- Market Access should be evaluated alongside Sales and Marketing—not treated as a separate or downstream consideration.
- The relative impact of Market Access and promotion can vary significantly by product and segment, making segment-level analysis critical.
- Conventional targeting can miss important opportunities when payer coverage and formulary dynamics are not incorporated into the segmentation framework.
